Assessment of fetal lung maturity: relationship of gestational age and pregnancy complications to phosphatidylglycerol levels.
Phosphatidylglycerol (PG) was measured in the pellet fraction of 863 amniotic fluid samples, and charts were reviewed for maternal disease, duration of gestation at collection, and outcome of pregnancy. PG was present at 32 to 34 weeks' gestation in 24.1% of samples; at 35 to 36 weeks, in 52.3%; and at 37 weeks, in 85.4%. Pre-eclamptic toxemia/hypertension, diabetes, premature rupture of membranes, and preterm labor all had earlier appearance of PG than a comparison group. There was no delay in lung maturity in gestational diabetics or Rh isoimmunization. Infants of patients with overt diabetes with PG greater than or equal to 0.5% did not develop respiratory distress syndrome. This value appeared in 30% of diabetic patients by 35 to 36 weeks and in 76.9% by 37 weeks' gestation.
D000653:Amniotic Fluid / Q000032:analysis; D003920:Diabetes Mellitus / Q000097:blood; D005260:Female; D005325:Fetal Organ Maturity; D005865:Gestational Age; D006801:Humans; D006973:Hypertension / Q000097:blood; D008168:Lung / Q000196:embryology*; D007752:Obstetric Labor, Premature / Q000097:blood; D010715:Phosphatidylglycerols / Q000097:blood*; D011225:Pre-Eclampsia / Q000097:blood; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood*; D011263:Pregnancy Trimester, Third; D011379:Prognosis; D012422:Rupture, Spontaneous / Q000097:blood
D010715:Phosphatidylglycerols